Newsroom

法国里尔--(BUSINESS WIRE)--(美国商业资讯)-- 作为植物基配料、赋形剂和药用解决方案领域的全球领导者，Roquette将于2026年5月5日至5月7日在巴塞罗那举行的2026年欧洲国际营养保健食品展上展示其扩展后的产品组合。Roquette的解决方案旨在助力消费者健康品牌前瞻布局未来，并加速以消费者为中心的日常健康创新。 随着消费者期望不断提升、货架竞争日益激烈，膳食补充剂、非处方药(OTC)品牌以及合同研发与生产组织(CDMO)在推出清洁标签产品方面面临更大压力，这些产品需兼具功效、卓越感官体验、合规保障及快速上市能力。在2026年欧洲国际营养保健食品展上，Roquette将展示其作为多元化合作伙伴的价值，为客户提供从早期概念到商业化上市的全流程支持，涵盖硬胶囊、软胶囊、软糖、（迷你）片剂和咀嚼片等多种剂型。 植物基实力融合高端性能，满足多元膳食需求 Roquette健康与制药解决方案业务部全球消费者健康营销负责人Laura Owens表示：“Roquette的消费者健康业务建立在深受信赖且富有创新的配料品牌积淀之上。我们致力于为补充剂品牌和CDMO提供解决方案，...

SEATTLE--(BUSINESS WIRE)--F5, Inc. (NASDAQ: FFIV), the global leader in delivering and securing every app and API, announced it will host its Analyst and Investor Meeting on Thursday, May 28, 2026, starting at 1:00 pm ET in New York, NY. A live webcast and replay of the event will be accessible from the events & presentations page of the investor relations portion of f5.com. About F5 F5, Inc. (NASDAQ: FFIV) is the global leader that delivers and secures every app. Backed by three decades of...

BELLEVUE, Wash.--(BUSINESS WIRE)--PACCAR Inc’s Board of Directors today approved an increase in the regular quarterly cash dividend from thirty-three cents ($.33) per share to thirty-five cents ($.35) per share. The dividend will be payable on June 3, 2026, to stockholders of record at the close of business on May 13, 2026. Mark Pigott, executive chairman, shared, “PACCAR has generated excellent shareholder returns and profitability for decades. PACCAR has delivered annual dividends, including...

NEW YORK--(BUSINESS WIRE)--Vensica Medical, azienda di fase clinica specializzata nello sviluppo di soluzioni di somministrazione terapeutica senza ago per malattie urologiche, oggi ha annunciato che la Food and Drug Administration (FDA) statunitense ha autorizzato la domanda di nuovo farmaco sperimentale (IND, investigational new drug) dell'Azienda per avviare uno studio clinico di fase 2 su ViXe. Lo studio valuterà Vibe®, il sistema di somministrazione senza ago, basato su ultrasuoni, in comb...

NEW YORK--(BUSINESS WIRE)--Vensica Medical, een bedrijf in klinische fase dat injectieloze therapeutische toedieningsoplossingen ontwikkelt voor urologische aandoeningen, maakte vandaag bekend dat de Amerikaanse FDA (U.S. Food & Drug Administration) goedkeuring heeft gegeven voor de IND-toepassing (Investigational New Drug) van het bedrijf om een klinische studie van Fase 2 te starten voor ViXe. Deze studie zal het Vibe® injectieloze systeem op basis van ultrasoon geluid voor toediening van...

NEW YORK--(BUSINESS WIRE)--Vensica Medical, une société au stade clinique développant des solutions d'administration thérapeutique sans aiguille pour les maladies urologiques, a annoncé aujourd'hui que l'Agence américaine des produits alimentaires et médicamenteux (FDA) avait approuvé sa demande d'autorisation de nouveau médicament expérimental (IND) en vue de lancer un essai clinique de phase 2 sur le ViXe. L'étude évaluera son système d'administration de médicaments sans aiguille Vibe® basé s...

NEW YORK--(BUSINESS WIRE)--Vensica Medical, ein Unternehmen im klinischen Stadium, das nadelfreie therapeutische Verabreichungslösungen für urologische Erkrankungen entwickelt, gab heute bekannt, dass die US-amerikanische Food and Drug Administration (FDA) den Antrag des Unternehmens auf Zulassung als neues Prüfpräparat (Investigational New Drug, IND) zur Einleitung einer klinischen Phase-2-Studie mit ViXe genehmigt hat. Die Studie wird das ultraschallbasierte, nadelfreie Medikamentenverabreich...

NUEVA YORK--(BUSINESS WIRE)--Vensica Medical, empresa en fase clínica especializada en el desarrollo de soluciones terapéuticas sin agujas para enfermedades urológicas, anunció hoy que la Administración de Alimentos y Medicamentos de Estados Unidos (FDA) ha concedido la autorización necesaria para que la empresa inicie un ensayo clínico de fase II de ViXe. El estudio evaluará el sistema Vibe®, una tecnología de administración de fármacos sin agujas basada en ultrasonidos, en combinación con Xeo...

SÃO PAULO--(BUSINESS WIRE)--Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2025 Annual Report on Form 20-F was filed on March 24, 2026 with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contac...

SAN DIEGO--(BUSINESS WIRE)--A ASTERRA apresentará soluções de infraestrutura baseadas em satélite na IWA Water Loss 2026, o encontro global da Associação Internacional da Água (IWA) para gestão de perdas de água. A conferência, que acontecerá de 26 a 29 de abril de 2026 no Rio de Janeiro, é o principal fórum internacional do setor sobre água não faturada (ANF), inovação e gestão sustentável da água. Com uma mensagem focada em transformar perdas de água em ação climática, a ASTERRA demonstrará c...